G B Mancini

Summary

Affiliation: University of British Columbia
Country: Canada

Publications

  1. ncbi Coronary angiographic changes in patients with cardiac events in the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT)
    G B John Mancini
    University of British Columbia, Vancouver, British Columbia, Canada
    Am J Cardiol 90:776-8. 2002
  2. ncbi Coronary stent restenosis in patients treated with cilostazol
    John S Douglas
    Emory University School of Medicine, Atlanta, GA, USA
    Circulation 112:2826-32. 2005
  3. ncbi Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study
    Sammy Y Chan
    Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, Canada
    BMC Clin Pharmacol 8:10. 2008
  4. ncbi Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease
    G B John Mancini
    Division of Cardiology, Vancouver Hospital, Jack Bell Research Centre, University of British Columbia, Vancouver, British Columbia, Canada
    J Am Coll Cardiol 47:2554-60. 2006
  5. ncbi Validation of a new ultrasound method for the measurement of carotid artery intima medial thickness and plaque dimensions
    G B John Mancini
    Cardiovascular Imaging Research Core Laboratory, Vancouver Hospital, and University of British Columbia, Vancouver, Canada
    Can J Cardiol 20:1355-9. 2004
  6. ncbi Quantitative results of baseline angiography and percutaneous coronary intervention in the COURAGE trial
    G B John Mancini
    Vancouver Hospital, Cardiovascular Imaging Research Core Laboratory, University of British Columbia, Vancouver, Canada
    Circ Cardiovasc Qual Outcomes 2:320-7. 2009
  7. ncbi The 'double dip' hypothesis: simultaneous prevention of cardiovascular and pulmonary morbidity and mortality using angiotensin II type 1 receptor blockers
    G B John Mancini
    Division of Cardiology, University of British Columbia, Vancouver, Canada
    Can J Cardiol 21:519-23. 2005
  8. ncbi Angiotensin II type 1 receptor blocker inhibits pulmonary injury
    G B John Mancini
    Department of Medicine, Division of Cardiology, University of British Columbia and Vancouver Coastal Research Institute, Vancouver, Canada
    Clin Invest Med 28:118-26. 2005
  9. ncbi Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation
    G B John Mancini
    Vancouver Hospital and Health Sciences Centre, University of British Columbia, Canada
    Can J Cardiol 18:1309-16. 2002
  10. ncbi Antiatherosclerotic effects of calcium channel blockers
    G B John Mancini
    Department of Medicine, The University of British Columbia, Vancouver, Canada
    Prog Cardiovasc Dis 45:1-20. 2002

Detail Information

Publications52

  1. ncbi Coronary angiographic changes in patients with cardiac events in the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT)
    G B John Mancini
    University of British Columbia, Vancouver, British Columbia, Canada
    Am J Cardiol 90:776-8. 2002
  2. ncbi Coronary stent restenosis in patients treated with cilostazol
    John S Douglas
    Emory University School of Medicine, Atlanta, GA, USA
    Circulation 112:2826-32. 2005
    ..We undertook a randomized, double-blind, placebo-controlled trial to determine whether cilostazol, a drug that suppresses intimal proliferation, would reduce renarrowing in patients after stent implantation in native coronary arteries...
  3. ncbi Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study
    Sammy Y Chan
    Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, Canada
    BMC Clin Pharmacol 8:10. 2008
    ..We treated subjects with hyperlipidemia sequentially with statins and fibrates, the 2 main classes of lipid lowering therapy and studied changes in NMR lipoprotein subclasses...
  4. ncbi Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease
    G B John Mancini
    Division of Cardiology, Vancouver Hospital, Jack Bell Research Centre, University of British Columbia, Vancouver, British Columbia, Canada
    J Am Coll Cardiol 47:2554-60. 2006
    ....
  5. ncbi Validation of a new ultrasound method for the measurement of carotid artery intima medial thickness and plaque dimensions
    G B John Mancini
    Cardiovascular Imaging Research Core Laboratory, Vancouver Hospital, and University of British Columbia, Vancouver, Canada
    Can J Cardiol 20:1355-9. 2004
    ..Carotid ultrasound is an accepted method for the detection of subclinical atherosclerosis. Valid methods that allow quantitation of carotid atheroma burden may be useful for stratifying risk...
  6. ncbi Quantitative results of baseline angiography and percutaneous coronary intervention in the COURAGE trial
    G B John Mancini
    Vancouver Hospital, Cardiovascular Imaging Research Core Laboratory, University of British Columbia, Vancouver, Canada
    Circ Cardiovasc Qual Outcomes 2:320-7. 2009
    ..COURAGE compared outcomes in stable coronary patients randomized to optimal medical therapy plus percutaneous coronary intervention (PCI) versus optimal medical therapy alone...
  7. ncbi The 'double dip' hypothesis: simultaneous prevention of cardiovascular and pulmonary morbidity and mortality using angiotensin II type 1 receptor blockers
    G B John Mancini
    Division of Cardiology, University of British Columbia, Vancouver, Canada
    Can J Cardiol 21:519-23. 2005
    ..Moreover, angiotensin II is also a direct mediator of lung injury; interruption of this mechanism of injury might simultaneously prevent both cardiovascular and pulmonary morbidity and mortality in patients with chronic lung disease...
  8. ncbi Angiotensin II type 1 receptor blocker inhibits pulmonary injury
    G B John Mancini
    Department of Medicine, Division of Cardiology, University of British Columbia and Vancouver Coastal Research Institute, Vancouver, Canada
    Clin Invest Med 28:118-26. 2005
    ..The purpose of this study was to evaluate the effects of an angiotensin II type 1 receptor blocker, valsartan, on systemic, cellular, and fibrotic consequences of pulmonary injury induced by the anti-neoplastic antibiotic, bleomycin...
  9. ncbi Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation
    G B John Mancini
    Vancouver Hospital and Health Sciences Centre, University of British Columbia, Canada
    Can J Cardiol 18:1309-16. 2002
    ..ACEIs have been shown to improve endothelial dysfunction in many clinical settings...
  10. ncbi Antiatherosclerotic effects of calcium channel blockers
    G B John Mancini
    Department of Medicine, The University of British Columbia, Vancouver, Canada
    Prog Cardiovasc Dis 45:1-20. 2002
    ..This article reviews the currently available evidence of antiatherosclerotic effects of CCBs in animal models and in clinical trials...
  11. ncbi Post hoc analysis of coronary findings from the prospective randomized evaluation of the vascular effects of the Norvasc trial (PREVENT)
    G B John Mancini
    Vancouver Hospital, Vancouver, BC, Canada
    Am J Cardiol 89:1414-6. 2002
  12. ncbi Association of skin cholesterol content, measured by a noninvasive method, with markers of inflammation and Framingham risk prediction
    G B John Mancini
    Lipid Clinic/Healthy Heart Program and the Atherosclerosis Reversal Clinic, St. Paul's Hospital and Jack Bell Research Centre, University of British Columbia, Vancouver, British Columbia, Canada
    Am J Cardiol 89:1313-6. 2002
  13. ncbi Redefining the normal angiogram using population-derived ranges for coronary size and shape: validation using intravascular ultrasound and applications in diverse patient cohorts
    G B John Mancini
    Cardiovascular Imaging Research Core Laboratory, Division of Cardiology, University of British Columbia, Vancouver Hospital, 10209 2775 Laurel Street, Vancouver, BC, Canada, V5Z 1M9
    Int J Cardiovasc Imaging 23:441-53. 2007
    ..To develop a method for quantitating coronary angiographic abnormalities of segmental size and shape (tapering) in comparison to gender- and segment-specific, population derived, normal values...
  14. ncbi Why were the results of the Heart Outcomes Prevention Evaluation (HOPE) trial so astounding?
    G B Mancini
    Department of Medicine, University of British Columbia and Vancouver General Hospital, Vancouver, Canada
    Can J Cardiol 17:15A-7A. 2001
    ..The benefits of ACE inhibitor therapy that were observed were likely due to a variety of mechanisms, not just a reduction in blood pressure...
  15. ncbi Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference
    G B John Mancini
    Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    Can J Cardiol 27:635-62. 2011
    ..The ultimate goal is to ensure that patients who warrant cardiovascular risk reduction can be treated optimally, safely, and confidently with statin medications or alternatives when warranted...
  16. ncbi Validation of an automated method for assessing brachial artery endothelial dysfunction
    G B John Mancini
    Cardiac Imaging Research Laboratory, Jack Bell Research Centre, Atherosclerosis Reversal Clinic, St Paul s Hospital, University of British Columbia, Vancouver
    Can J Cardiol 18:259-62. 2002
    ..Automated image analysis of the ultrasound images would facilitate implementation of such measurements in high throughput clinics and/or large clinical trials...
  17. ncbi Angiographic and clinical outcomes of drug-eluting versus bare metal stent deployment in the Occluded Artery Trial
    Vladimir Dzavik
    Division of Cardiology, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada
    Catheter Cardiovasc Interv 73:771-9. 2009
    ..We aimed to determine if stenting of the target occlusion in OAT with drug-eluting stents (DES) was associated with more favorable angiographic results and clinical outcome when compared with treatment with BMS...
  18. ncbi Assessment of novel risk factors in patients at low risk for cardiovascular events based on Framingham risk stratification
    Jasmine Grewal
    Department of Medicine, University of British Columbia, St. Paul's Hospital, Vancouver, BC
    Clin Invest Med 26:158-65. 2003
    ....
  19. ncbi Carotid intima-media thickness as a measure of vascular target organ damage
    G B Mancini
    Vancouver Hospital and Health Sciences Centre, 3300 950 West 10th Avenue, Vancouver, BC V5E 4Z3, Canada
    Curr Hypertens Rep 2:71-7. 2000
    ..The method appears highly suited to the goal of detecting asymptomatic vascular target organ damage, which may greatly assist with assessment of risk and selection of appropriate, preventive, strategies for management of disease...
  20. ncbi Long-term use of angiotensin-converting enzyme inhibitors to modify endothelial dysfunction: a review of clinical investigations
    G B Mancini
    Department of Medicine, University of British Columbia, Vancouver Hospital and Health Sciences Centre
    Clin Invest Med 23:144-61. 2000
    ..The purpose of this paper is to review clinical studies assessing the effect of long-term, oral ACE inhibition on endothelial dysfunction in specific disease syndromes and to identify areas requiring further research...
  21. ncbi Overview of the prospective randomized evaluation of the vascular effects of Norvasc (amlodipine) trial: PREVENT
    G B Mancini
    Vancouver Hospital and Health Sciences Centre, Vancouver, Canada
    Can J Cardiol 16:5D-7D. 2000
    ..This brief report provides an overview and assessment of the implications of these findings...
  22. ncbi Dietary measures and exercise training contribute to improvement of endothelial function and atherosclerosis even in patients given intensive pharmacologic therapy
    Sammy Y Chan
    Division of Cardiology, Department of Medicine, University of British Columbia, Canada
    J Cardiopulm Rehabil 26:288-93. 2006
    ..Atherosclerosis contributes to cardiovascular mortality and morbidity even with aggressive lipid management. Our objective is to determine whether a combined pharmacological and lifestyle intervention can improve atherosclerosis...
  23. ncbi Percutaneous coronary intervention in the Occluded Artery Trial: procedural success, hazard, and outcomes over 5 years
    Christopher E Buller
    Vancouver General Hospital, Vancouver, British Columbia, Canada
    Am Heart J 158:408-15. 2009
    ..The influence of PCI failure, procedural hazard, and crossover on trial results has not been reported...
  24. ncbi Coronary atherosclerosis in anorexia nervosa
    Carl Laird Birmingham
    Eating Disorders Program, St Paul s Hospital, University of British Columbia, Vancouver, Canada
    Int J Eat Disord 34:375-7. 2003
    ..Chest pain is a common complaint in patients with anorexia nervosa (AN). Of those who experience chest pain, about 20% meet the diagnostic criteria for typical or atypical angina...
  25. ncbi Subclinical atherosclerosis in subjects with family history of premature coronary artery disease
    Catalin Taraboanta
    Faculty of Medicine, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    Am Heart J 155:1020-1026.e1. 2008
    ....
  26. ncbi The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy
    Jacqueline Saw
    Division of Cardiology, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    JACC Cardiovasc Interv 1:654-9. 2008
    ..The purpose of this study was to evaluate the effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention (PCI) with glycoprotein (GP) IIb/IIIa blockade...
  27. ncbi Adaptive statistical iterative reconstruction: assessment of image noise and image quality in coronary CT angiography
    Jonathon Leipsic
    Department of Radiology and Department of Medicine, Division of Cardiology, University of British Columbia, St Paul s Hospital, 1081 Burrard St, Vancouver, BC V6N 2N7, Canada
    AJR Am J Roentgenol 195:649-54. 2010
    ..The purpose of our study was to determine the effect of Adaptive Statistical Iterative Reconstruction (ASIR) on cardiac CT angiography (CTA) signal, noise, and image quality...
  28. ncbi The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease
    Sammy Y Chan
    Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    J Am Coll Cardiol 42:1037-43. 2003
    ..Preserved endothelial function attenuates the risk of future events associated with a high plaque burden...
  29. ncbi Estimated radiation dose reduction using adaptive statistical iterative reconstruction in coronary CT angiography: the ERASIR study
    Jonathon Leipsic
    Department of Radiology and Department of Medicine, Division of Cardiology, University of British Columbia, Vancouver, BC, Canada
    AJR Am J Roentgenol 195:655-60. 2010
    ..The objective of our study was to assess the impact of Adaptive Statistical Iterative Reconstruction (ASIR) on radiation dose and study quality for coronary CT angiography (CTA)...
  30. ncbi Ankle brachial index screening for occult vascular disease is not useful in HIV-positive patients
    Kevin Johns
    University of British Columbia, Vancouver, BC, Canada
    AIDS Res Hum Retroviruses 26:955-9. 2010
    ..ABI was not useful in detecting occult vascular disease in HIV-positive patients and offers no additional information to that derived from cardiovascular risk stratification...
  31. ncbi An update on lipid-lowering therapy
    J D Barth
    Division of Cardiology, Vancouver Hospital and Health Sciences Centre, University of British Columbia, Canada
    Curr Opin Lipidol 6:32-7. 1995
    ..More widespread implementation of screening programmes to identify suitable patients for lipid-lowering therapy may help prevent the excess utilization of health care resources...
  32. ncbi A comparison of quantitative coronary angiography systems using a unique set of in vivo coronary stenosis images
    G B Mancini
    University of British Columbia, Vancouver Hospital and Health Sciences Centre, Vancouver, Canada
    Can J Cardiol 17:785-91. 2001
    ..To compare the accuracy and precision of measurements of minimum lumen diameter (MLD) among two existing, and one new, quantitative coronary angiography systems...
  33. ncbi Retrieval and analysis of particulate debris after saphenous vein graft intervention
    J G Webb
    St Paul s Hospital, University of British Columbia, Vancouver, Canada
    J Am Coll Cardiol 34:468-75. 1999
    ..This study was designed to evaluate the composition and quantity of particulate debris resulting from vein graft intervention...
  34. ncbi Immigration presents a potential increased risk for atherosclerosis
    Scott A Lear
    Simon Fraser University, British Columbia, Canada
    Atherosclerosis 205:584-9. 2009
    ..The purpose of this study was to determine the independent association of time since immigration with sub-clinical atherosclerosis in immigrants of Chinese, European and South Asian origin...
  35. ncbi Normal angiographic tapering of the coronary arteries
    Mohammad Zubaid
    Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, Canada
    Can J Cardiol 18:973-80. 2002
    ..Similar tapering results were obtained in men. CONCLUSIONS: The estimation of an expected magnitude of tapering of coronary arteries may identify diseased segments that are not angiographically stenotic...
  36. ncbi Initial experience with a novel coronary rinsing and thrombectomy system: "Rinspiration"
    John Webb
    Cardiology Department of St. Paul's Hospital, Vancouver, British Columbia, Canada
    J Invasive Cardiol 18:188-92. 2006
    ..CONCLUSIONS: The Rinspiration system appears capable of safely removing intracoronary thrombus and warrants further evaluation...
  37. ncbi Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorv
    F D Richard Hobbs
    Primary Care Clinical Sciences Building, University of Birmingham, Edgbaston, UK
    Int J Cardiol 110:242-50. 2006
    ..The JEWEL study program will investigate the use of single-pill amlodipine/atorvastatin as a strategy to improve management of these patients...
  38. ncbi Effect of PCI on quality of life in patients with stable coronary disease
    William S Weintraub
    Christiana Care Health System, Newark, DE 19718, USA
    N Engl J Med 359:677-87. 2008
    ..It has not been clearly established whether percutaneous coronary intervention (PCI) can provide an incremental benefit in quality of life over that provided by optimal medical therapy among patients with chronic coronary artery disease...
  39. ncbi Vascular structure versus function: is endothelial dysfunction of independent prognostic importance or not?
    G B John Mancini
    J Am Coll Cardiol 43:624-8. 2004
  40. ncbi The number needed to harm: is it too optimistic?
    G B John Mancini
    Can J Cardiol 20:1375; author reply 1376. 2004
  41. ncbi Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy
    Leslee J Shaw
    Emory University School of Medicine, Atlanta, GA 30306, USA
    Circulation 117:1283-91. 2008
    ....
  42. ncbi The relationship of three common definitions of the metabolic syndrome with sub-clinical carotid atherosclerosis
    Erica Paras
    School of Kinesiology, Simon Fraser University, Harbour Centre Campus, 515 West Hastings St Vancouver, British Columbia, Canada V6B 5K3
    Atherosclerosis 198:228-36. 2008
    ....
  43. ncbi Statin therapy and the management of acute coronary syndromes
    Anatoly Langer
    Canadian Heart Research Centre and St Michael s Hospital, University of Toronto, Toronto, Canada
    Can J Cardiol 19:921-7. 2003
    ....
  44. ncbi Clarion call for trials assessing "cardiopulmonary" agents to reduce morbidity and mortality in inflammatory lung diseases
    G B John Mancini
    Chest 131:950-1. 2007
  45. ncbi Optimal medical therapy with or without PCI for stable coronary disease
    William E Boden
    Western New York Veterans Affairs Healthcare Network and Buffalo General Hospital SUNY, Buffalo, NY 14203, USA
    N Engl J Med 356:1503-16. 2007
    ....
  46. ncbi Reporting measures of endothelial dysfunction independent of baseline arterial diameter
    G B John Mancini
    Am J Cardiol 94:1222-3. 2004
  47. ncbi Surrogate markers for cardiovascular disease: structural markers
    G B John Mancini
    Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minn 55455, USA
    Circulation 109:IV22-30. 2004
  48. ncbi Adjunctive use of the Rinspiration system for fluidic thrombectomy during primary angioplasty: the Rinspiration international registry
    Marco De Carlo
    Cardiothoracic and Vascular Department, University of Pisa, Pisa, Italy
    Catheter Cardiovasc Interv 72:196-203. 2008
    ..The aim of this study was to investigate the safety and efficacy of an innovative thrombectomy device, the Rinspiration System, which simultaneously "rinses" the vessel with turbulent flow and aspirates thrombus...
  49. ncbi ACE inhibitors: back to prime time?
    Milan Gupta
    Heart 93:1015-6. 2007
  50. ncbi The evolving pattern of symptomatic coronary artery disease in the United States and Canada: baseline characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial
    William E Boden
    VA Connecticut Healthcare System, West Haven, Connecticut, USA
    Am J Cardiol 99:208-12. 2007
    ....
  51. ncbi Randomized trial of percutaneous coronary intervention for subacute infarct-related coronary artery occlusion to achieve long-term patency and improve ventricular function: the Total Occlusion Study of Canada (TOSCA)-2 trial
    Vladimir Dzavik
    University Health Network, University of Toronto, Toronto, Ontario, Canada
    Circulation 114:2449-57. 2006
    ....
  52. ncbi Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424
    William E Boden
    VA Connecticut Healthcare System, West Haven, CT, USA
    Am Heart J 151:1173-9. 2006
    ....